Shopping Cart

There are no products in your cart.

A/Prof. Peter Janes

Head, Receptor Biology Laboratory

More about A/Prof. Peter Janes

I am interested in how our bodies function at a cellular level, and how normal developmental processes can become hijacked by tumours - in particular, how key proteins that drive cancer development can be identified and targeted in an effort to specifically kill tumour cells and avoid harmful side-effects.

I focus on cell surface receptors and associated proteins that are more prominent in tumours than in normal tissues, with the aim of developing antibodies that will bind with or block these proteins. I completed my PhD studies on HER/erbB receptors in breast cancer while in Sydney, followed by postdoctoral positions at the National Institute for Medical Research, London, and the Peter MacCallum Cancer Centre, Melbourne. I worked with the late Martin Lackmann at Monash University and I am currently continuing with the research focus I started there in my new position in the Tumour Targeting Program at the ONJCRI.

Education

Bachelor of Science (Honours), University of Sydney, Australia

PhD, Garvan Institute, University of New South Wales, Australia

Current Appointments

Head, Receptor Biology Laboratory, Olivia Newton-John Cancer Research Institute

Adjunct Associate Professor, School of Cancer Medicine, La Trobe University

Adjunct Senior Research Fellow, Department of Biochemistry, Monash University

Achievements

A.S. Glover Fellowship, Melbourne University

Howard Florey Centenary Fellowship, NHMRC

Career Development Award/RD Wright Fellowship, NHMRC

Recent Publications

Seegar TC, Killingsworth LB, Saha N, Meyer PA, Patra D, Zimmerman B, Janes PW, Rubinstein E, Nikolov DB, Skiniotis G, Kruse AC, Blacklow SC. Structural Basis for Regulated Proteolysis by the α-Secretase ADAM10. Cell, 14; 171(7):1638-1648, 2017.
Atapattu L, Saha N, Chheang C, Eissman MF, Xu K, Vail ME, Hii L, Llerena C,Liu Z, Horvay K, Abud HE, Kusebauch U, Moritz RL, Ding B-S, Cao Z, Rafii S,Ernst M, Scott AM, Nikolov DB, Lackmann M and Janes PW. An activated form of ADAM 10 is tumor selective and regulates cancer stem-like cells and tumor growth. J Exp Med.213:1741-57 2016.
Mansour M, Nievergall E, Gegenbauer K, Llerena C, Atapattu L, Hallé M, Tremblay ML, Janes PW*, Lackmann M. 2016. PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling. J Cell Sci. 2016 Jan 15; 129(2):277-89 *Corresponding author.
Vail ME, Murone C, Hii L, Tan A, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM and Lackmann M. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 2014, 74 (16):4470-81.
To C, Farnsworth R, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, and Lackmann M. Hypoxia-controlled EphA3 marks a human endometrium derived multipotent mesenchymal stromal cell that supports vascular growth. PLoS One 9:e112106, 2014.

Email: peter.janes@onjcri.org.au